Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 17Neoplasm Metastasis 8Rectal Neoplasms 6Colonic Neoplasms 4Uveal Melanoma 3Stomach Neoplasms 2Neoplasms 2Recurrence 1Pancreatic Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colorectal Cancer Metastatic 1Carcinoid Tumor 1Breast Neoplasms 1Biliary Tract Neoplasms 1Advanced Colorectal Cancer 1

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Recurrence × aflibercept × Clear all
NCT04810585 2021-03-23

Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer

Yonsei University

Phase 4 Unknown
153 enrolled
Gastrointestinal

Recurrence, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡